CALIMOD PRESENTS

ILXIR

Il-10 in response

The problem

3.1 million Americans have inflammatory bowel disease (IBD)

Current biologics often require injections and have short half-life
Cytokines are a key player in inflammation

Our solution

Mutant IL-10 (MIL-10) engineered for higher stability and activity

Probiotic chassis: Lactobacillus plantarum for safe delivery
Trigger: responds to inflammatory cytokines (e.g., TNF-α) so it acts only when needed
Accessible delivery: potentially yogurt-based or capsule

Computational design (ThermoMPNN)
Plasmid construction & cloning
Expression in E. coli
ELISA, SDS-PAGE, Western blot
Statistical analysis

Explore our project